Retatrutide: Research Overview
Retatrutide (LY3437943) is a first-in-class tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is studied in metabolic research for its effects on body weight, energy expenditure, and glycemic regulation.
Triple receptor agonism
Retatrutide is distinguished by acting on three incretin and metabolic receptor systems at once. The GLP-1 axis contributes satiety and glycemic modulation; the GIP axis influences insulin secretion and adipose signaling; and the glucagon receptor component is thought to enhance lipolysis and energy expenditure. This third arm is what differentiates retatrutide from dual GLP-1/GIP agonists such as tirzepatide.
Published clinical research
A Phase 2 clinical trial published in the New England Journal of Medicine (2023) reported mean body-weight reductions of approximately 17% over 24 weeks at the highest dose studied — among the largest effects reported for any pharmacological intervention in obesity research to date. Preclinical work supports the role of the glucagon component in increasing whole-body energy expenditure.
Purity and verification
Pokai Research Retatrutide is third-party tested by Janoshik Analytical at 99.82% purity (batch 26030313). The Certificate of Analysis is published on the product page with a direct Janoshik verification link.
Frequently asked questions
What is Retatrutide and what receptor systems does it target?
Retatrutide (LY3437943) is a tri-agonist research peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data published in NEJM (2023) reported roughly 17% mean body-weight reduction over 24 weeks at the highest dose studied, among the largest effects reported in obesity research.
Source: N Engl J Med (2023) · PubMedWhat role does GIP receptor activation play in energy metabolism?
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by K-cells of the duodenum in response to nutrient ingestion. Beyond its classical role in potentiating glucose-stimulated insulin secretion, GIP receptors are expressed in adipose tissue, where GIP promotes lipid storage under fed conditions. Paradoxically, antagonism of the GIP receptor in rodent models reduces obesity, while GIP receptor agonism in the context of combined GLP-1 co-agonism (as in tirzepatide) enhances weight loss beyond GLP-1 alone. The mechanistic explanation for this apparent duality remains an active area of metabolic research.
Source: Cell Metab (2022) · PubMedHow is peptide purity measured and why does it matter?
Peptide purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC) and confirmed by mass spectrometry. These techniques quantify the proportion of the target compound relative to impurities such as deletion sequences, oxidized variants, or solvent residues. Research applications require high purity — commonly ≥98% — to ensure that observed biological effects can be attributed to the intended molecule rather than contaminants. Independent third-party certificates of analysis (COAs) provide an objective record of purity at the time of synthesis.
Source: J Pept Sci (2019) · PubMedWhat is a Certificate of Analysis (COA)?
A Certificate of Analysis (COA) is a document from an accredited analytical laboratory confirming a compound's identity, purity, and potency. For research peptides it typically includes HPLC chromatograms and mass spectrometry data. Independent third-party COAs are the gold standard for verifying compound quality.
Source: USP General Chapter ⟨1058⟩ · PubMed